For the purposes of getting straight to the point, Peptides are a sequence of amino acids. The use of Peptides, is a fascinating medical breakthrough for patients who are interested in the benefits of optimized health including, fat loss and anti-catabolic muscle tissue enhancement, anti-aging, bone health, immune health, gut healing, cardiovascular and neuroprotective health, and various types of tissue repair, including rapid injury rehabilitation and post-surgery recovery.
Tesamorelin is a chemically synthesized compound that is similar to growth-hormone releasing hormone. Indeed, Tesamorelin has the exact same 44 amino acids as growth-hormone releasing hormone. Growth-hormone releasing hormone, as its name implies, acts on the pituitary gland (a pea-like gland located in the brain) to release growth-hormone. Growth-hormone is an essential peptide that stimulates growth and cell regeneration in the human body.
By virtue of stimulating the release of growth-hormone, Tesamorelin bestows a whole host of benefits for the human body. These include increased retention of calcium, increased protein synthesis and muscle growth and increased breakdown of fat. Indeed, Tesamorelin has been shown to reduce visceral fat, that is the fat surrounding the internal organs in a clinical trial conducted in 2017. Much of the abdominal obesity we see in adults today arises from visceral fat.
In fact, Tesamorelin has also been shown to increase one’s metabolism. A study conducted in 2014 showed that just 12 months of treatment showed improvements in mitochondrial function. Mitochondria are the “powerhouses” of our cells and are responsible for producing the energy our cells require to fuel activity.
The safety of Tesamorelin has been studied extensively. 2 studies in 2010 and 2017 showed that Tesamorelin is tolerated well and did not incur and serious adverse effects in patients prescribed with it, even over longer durations (e.g. 12 weeks).
*To make matters markedly better, Tesamorelin is known to deliver the same results as Human Growth Hormone at a much more affordable price!
Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab. 2013;99(1):338-43.
Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015;10(10):e0140358. Published 2015 Oct 12. doi:10.1371/journal.pone.0140358
Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010; 95: 4291–4304. doi: 10.1210/jc.2010-0490
Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. Published 2017 Jun 15. doi:10.1371/journal.pone.0179538